Search

Patients who benefit-Backup

A STATE-OF-THE-ART TREATMENT OPTION FOR PATIENTS AT HIGH RISK FOR SURGERY TriClip™ TEER is a low risk,5 minimally invasive, non-surgical treatment option for symptomatic patients with severe…
Connext Live

© Abbott 2023. All rights reserved. 9-EH-5-14560-01 09-2023
Clinical Data

GREATER SAFETY COMPARED WITH SURGICAL CLOSURE The Amplatzer™ Septal Occluder is the most studied transcatheter atrial septal defect (ASD) closure device available today, with over 25+ years of…
Clinical Data

SURGICAL VALVE SOLUTIONS DURABILITY THAT WITHSTANDS THE LONG-TERM TEST OF TIME 10 YEARS 93.8%* Freedom from SVD, All patient ages (Epic™ Mitral Valve)1 96.3%* Freedom from SVD, All patient…
Connext TV

© Abbott 2023. All rights reserved. 9-EH-5-14558-01 09-2023
Overview

THE PIONEER IN VENTRICULAR SEPTAL OCCLUDERS1 Abbott’s Amplatzer line not only pioneered structural heart defect occluders, it also retains a leadership position in structural heart innovation and…
Patients who benefit

The importance of treating patients with VSD AFTER RECEIVING THE AMPLATZER™ VSD OCCLUDER JOZEF, AMAZED AT HIS ENERGY AND ABILITY TO WALK LONG DISTANCES AGAIN, SAID: “I feel joy deep inside…
Key Features

Choose between two Amplatzer™ devices for Muscular VSD Closure Abbott’s 2 muscular VSD occluders allow for either a femoral or an arterial delivery. Amplatzer™ Muscular VSD Occluder …
Clinical Data

AMPLATZER™ MUSCULAR VSD OCCLUDER DEMONSTRATED CLOSURE SUCCESS IN PATIENTS WITH VSD The Amplatzer™ Muscular VSD Occluder was evaluated in a prospective, non-randomized, multi-center clinical study…
Overview

SWITCH TO THE interventional VIEW For more information specific to interventional cardiology regarding PDA closure PATENT DUCTUS ARTERIOSUS (PDA) A PDA can cause left-to-right…